NEWS | May 24, 2021

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles

By Press Release

As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.

LDS syringes maximize dose efficiency and allow for additional vaccinations to be obtained from vials. The utilization of LDS syringes will allow access to 20 percent more COVID-19 vaccine doses compared to non-LDS syringes. The investment will enable Retractable Technologies, Inc. to install two additional automated LDS safety syringe assembly lines at its manufacturing facility in Little Elm, Texas. The two additional assembly lines will enable the company to increase U.S. production capacity of LDS safety syringes by approximately 75%.

This project is part of the interagency effort to ensure timely availability of medical resources essential for national defense. This effort was led by the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, in collaboration with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the HHS Supply Chain and Industrial Base Assurance (SCIB) Steering Committee, and funded through the Defense Production Act (DPA) Title III Program at DOD.